Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...

The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade ...

FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates ...

The FDA said it is making 'enhancements' designed to help states develop programs for importing cheaper drugs from Canada.

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

BioNTech to invest £1B in UK R&D over 10 years, receives £129M government grant to build research centers and HQ in London, ...

Weill Cornell Medicine study shows cocaine vaccine triggers antibodies & reduces drug use in small trial, but effects modest.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

PureTech's deupirfenidone outperforms Roche's Esbriet in lung fibrosis trial, showing greater lung function preservation with ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

Mod­er­na pulls BLA for its Covid-flu shot: The com­pa­ny sug­gest­ed on its most re­cent … Get free access to a limited ...

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.